|
Market Cap (26-Jun) $7,311,981 (1,468th) |
Close (30-Jun) $0.042 |
Volume (30-Jun) 582,113 |
Shortsold (6-Dec) 611,822 (0.21%) (374th) |
|
52w High $0.021 |
52w Low $0.009 |
P/E 11.60 |
EPS -0.01 |
ACR released this announcement to the ASX on 12 November 2020, 9:54. The announcement is not marked as price sensitive, and is 29 page(s) in length and 0.96MB in size.
You can view all announcements from ACR and see how they appear on a price chart on the announcements page.
At the date of this announcement, ACR was 0.002% short sold according to ASIC data. It was ranked the 645th most shorted stock on the ASX. It is now ranked as the 374th most shorted stock on the ASX with 0.210% of total shares short sold as of the latest reported data (06 December 2024).
| Other Recent Announcements from ACR | |
|---|---|
| Appendix 3Y Brooke | 16 June 2023, 9:27 |
| Application for quotation of securities - ACR | 16 June 2023, 9:25 |
| 4th FDA ANDA approval received - Dapsone Gel, 5% | 7 June 2023, 10:35 |
| Appendix 3Y Dobinson | 24 May 2023, 10:11 |
| Annual General Meeting Presentation | 12 November 2020, 9:54 |
| Receipt of R&D Tax Incentive Rebate - Acrux Commercial | 27 October 2020, 11:01 |
| Receipt of R&D Tax Incentive Rebate - Acrux Pharma Pty Ltd | 15 October 2020, 10:36 |
You must be logged in to post a reply.
